AstraZeneca Applauds the Release of New Guideline for Cholesterol Management


Alisha Martin

Dr. Philip de Vane, Executive Director, U.S. Medical Affairs, AstraZeneca

This week marks an important milestone in guidelines for the treatment of patients at increased risk for atherosclerotic cardiovascular disease (ASCVD) as the American College of Cardiology (ACC) and American Heart Association (AHA) release a new clinical practice guideline for the management of blood cholesterol. 

The new 2013 ACC/AHA guideline has been highly anticipated across the healthcare industry, since the last update was issued nearly a decade ago. The guideline highlights statins as the preferred therapy for increased-risk patients to lower their high cholesterol, alongside a healthy lifestyle. What’s more, we have a treatment guideline that identifies patients most likely to benefit from statin therapy and for the first time distinguishes recommended intensity of statin therapy for specified patient groups.

This guideline reinforces the role of statins, such as CRESTOR® (rosuvastatin calcium), as an appropriate treatment option in increased-risk patients. When diet and exercise alone aren’t enough, CRESTOR is prescribed in adults, along with diet, to lower high cholesterol and to slow the buildup of plaque in arteries (atherosclerosis) as part of a treatment plan to lower cholesterol to goal.

At AstraZeneca, science and clinical research are at the root of everything we do across many therapeutic areas, including CVD. As leaders in this area, we are pleased that our research helped to inform the development of this important guideline, which we hope will help physicians identify the appropriate treatment for their increased-risk patients to reduce the risk of CVD, the leading cause of death in the United States.

For a copy of the “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults,” please visit: 

Approved Uses for CRESTOR® (rosuvastatin calcium) Tablets

When diet and exercise alone aren’t enough to lower cholesterol, adding CRESTOR can help. In adults, CRESTOR is prescribed along with diet to lower high cholesterol and slow the buildup of plaque in arteries as part of a treatment plan to lower cholesterol to goal.

CRESTOR is also prescribed to reduce the risk of heart attack and stroke in people without known heart disease but at increased risk based on age (men 50 years and older, women 60 years and older), elevated blood levels of hsCRP (a sign of inflammation that can be associated with increased risk of cardiovascular events), plus at least one additional risk factor (such as high blood pressure, low HDL “good” cholesterol, smoking, or family history of early heart disease).

Important Safety Information about CRESTOR

CRESTOR is not right for everyone. Do not take CRESTOR if you are nursing, pregnant or may become pregnant; have liver problems; or have had an allergic reaction to CRESTOR. Your doctor should do blood tests to check your liver before starting treatment and if you have symptoms of liver problems while taking CRESTOR. Call your doctor right away if you have unexplained muscle pain or weakness, especially with fever; have muscle problems that do not go away even after your doctor told you to stop taking CRESTOR; feel unusually tired; or have loss of appetite, upper belly pain, dark urine, or yellowing of skin or eyes. These could be signs of rare but serious side effects. Elevated blood sugar levels have been reported with statins, including CRESTOR. The most common side effects may include headache, muscle aches, abdominal pain, weakness, and nausea. Memory loss and confusion have also been reported with statins, including CRESTOR. Tell your doctor and pharmacist about other medicines you are taking.

Please see full Prescribing Information.